- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00051779
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid in patients with breast cancer metastatic to bone.
The study will also evaluate the possible effects of both study drugs on performance status, markers of bone metabolism, and skeletal events related to bone metastasis including elevated blood calcium levels, bone pain, metastatic lesions, complications and interventions. The levels of CAL in the blood will also be evaluated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
Springdale, Arkansas, United States, 72764
- Highlands Oncology Group
-
-
California
-
Concord, California, United States, 94520
- Bay Area Cancer Research Group
-
Greenbrae, California, United States, 94904
- California Cancer Care, Inc.
-
Los Angeles, California, United States
- Institute of Cancer Therapies
-
Vista, California, United States, 92083
- San Diego Cancer Research Institute
-
-
Colorado
-
Aurora, Colorado, United States, 80010-0510
- Anschutz Cancer Pavilion at the University of Colorado Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8028
- Yale University
-
-
Florida
-
Ft. Lauderdale, Florida, United States, 33308
- Holy Cross Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60612-3824
- Rush Cancer Institute
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0098
- University of Kentucky Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112-2278
- Louisiana State University
-
-
Maryland
-
Frederick, Maryland, United States, 21701
- Frederick Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Josephine Ford Cancer Center
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health
-
Southfield, Michigan, United States, 48076
- Southfield Oncology Institute, Inc.
-
-
Missouri
-
St. Louis, Missouri, United States, 63128
- St. Louis Center for Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Nevada Cancer Center
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, United States, 87505
- New Mexico Cancer Care Associates
-
-
New York
-
Bronx, New York, United States, 10467-2490
- Montefiore Medical Center
-
Brooklyn, New York, United States, 11235
- HemOnCare, P.C.
-
New York, New York, United States, 10021
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, United States, 12310
- SUNY Upstate Medical University
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
Cleveland, Ohio, United States, 44106
- Ireland Cancer Center
-
Columbus, Ohio, United States, 43235
- Hematology Oncology Consultants, Inc.
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Hershey Medical Center
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Palmetto Health
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic
-
Memphis, Tennessee, United States, 38104
- Boston Baskin Cancer Group
-
Memphis, Tennessee, United States, 38104
- The Boston Baskin Cancer Group
-
-
Texas
-
Corpus Christi, Texas, United States, 78412
- Cancer Specialists Of South Texas, Pa
-
Dallas, Texas, United States, 75230
- Center for Oncology Research & Treatment
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin-FMLH East Neoplastic Diseases and Related Disorders
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Major Inclusion Criteria - Others Stipulated within the Protocol
The study physician must assure you have/are:
- Must be a female at least 18 years of age and be using an effective form of birth control.
- A documented history of breast cancer and at least one bone metastasis that has not been previously treated by radiation or surgery, and is not anticipated to be treated within the next 24 weeks.
- A total body bone scan and other radiographic scan(s) performed on you within 4 weeks prior to or during the screening period sufficient to image all sites of bone metastases.
- You must be willing to perform a daily telephone diary and be willing to keep a paper diary and provide voluntary consent to participate in this study.
Major Exclusion Criteria - Others Stipulated within the Protocol
The study physician must assure you do not have/are not:
- A change in analgesic (pain relief) type medication during the screening period (example, non-narcotic to narcotic).
- Received radiation therapy to any bone metastasis or started a new course of chemotherapy within 3 weeks prior to the screening visit or during the screening period.
- Used any bisphosphonate type drug during the 30 days prior to the anticipated first dose of study drug
- Vertebral spine or weight-bearing bone metastasis that would place you at imminent risk for fracture or surgical intervention.
- Evidence of active infection or immune deficiency, renal failure, abnormal liver function, or a serum calcium level > 10.1 mg/dL.
- Use of any investigational drug within 30 days prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAL-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on CAL
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedLymphoid MalignanciesNetherlands
-
Youngstown State UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisCSL BehringCompleted
-
Lundquist Institute for Biomedical Innovation at...Eunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingObese | Healthy Lifestyle | MenUnited States
-
University of California, DavisNational Institute of Mental Health (NIMH); Washington University School of... and other collaboratorsEnrolling by invitationFirst Episode Psychosis (FEP)United States
-
Mansoura UniversityCompletedPrimary Teeth | Pulp Necroses | Infected Pulp | Root Canal TreatmentEgypt
-
Gilead SciencesTerminatedMantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
VA Office of Research and DevelopmentMiami VA Healthcare System; VA Salt Lake City Health Care SystemRecruitingGulf War Illness | Neurocognitive Dysfunction | Chronic FatigueUnited States